NUCLEOLIN and triple-negative breast carcinoma: Interestingly, most of the anti-NCL therapies have been evaluated in vitro and in vivo using triple-negative breast cancer models and showed strong cytotoxic effects, making NCL a powerful candidate for future evaluation of anti-NCL in breast cancer [6].